These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

561 related articles for article (PubMed ID: 15803438)

  • 1. Renal targeting of captopril using captopril-lysozyme conjugate enhances its antiproteinuric effect in adriamycin-induced nephrosis.
    Windt WA; Prakash J; Kok RJ; Moolenaar F; Kluppel CA; de Zeeuw D; van Dokkum RP; Henning RH
    J Renin Angiotensin Aldosterone Syst; 2004 Dec; 5(4):197-202. PubMed ID: 15803438
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific delivery of captopril to the kidney with the prodrug captopril-lysozyme.
    Kok RJ; Grijpstra F; Walthuis RB; Moolenaar F; de Zeeuw D; Meijer DK
    J Pharmacol Exp Ther; 1999 Jan; 288(1):281-5. PubMed ID: 9862782
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal targeting of captopril selectively enhances the intrarenal over the systemic effects of ACE inhibition in rats.
    Haverdings RF; Haas M; Navis G; Van Loenen-Weemaes AM; Meijer DK; De Zeeuw D; Moolenaar F
    Br J Pharmacol; 2002 Aug; 136(8):1107-16. PubMed ID: 12163343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of combining an ACE inhibitor and an angiotensin II receptor blocker on plasma and kidney tissue angiotensin II levels.
    Komine N; Khang S; Wead LM; Blantz RC; Gabbai FB
    Am J Kidney Dis; 2002 Jan; 39(1):159-64. PubMed ID: 11774115
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal-selective delivery and angiotensin-converting enzyme inhibition by subcutaneously administered captopril-lysozyme.
    Prakash J; van Loenen-Weemaes AM; Haas M; Proost JH; Meijer DK; Moolenaar F; Poelstra K; Kok RJ
    Drug Metab Dispos; 2005 May; 33(5):683-8. PubMed ID: 15673598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of anti-proteinuric therapy with angiotensin-converting-enzyme inhibition on renal protein catabolism in the adriamycin-induced nephrotic rat.
    Haas M; de Boer E; de Jong PE; Moolenaar F; Meijer DK; de Zeeuw D
    Clin Sci (Lond); 2003 Jul; 105(1):51-7. PubMed ID: 12636872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of captopril to the kidney reduces renal angiotensin-converting enzyme activity without affecting systemic blood pressure.
    Kok RJ; Haverdings RF; Grijpstra F; Koiter J; Moolenaar F; de Zeeuw D; Meijer DK
    J Pharmacol Exp Ther; 2002 Jun; 301(3):1139-43. PubMed ID: 12023548
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary sodium restriction specifically potentiates left ventricular ACE inhibition by zofenopril, and is associated with attenuated hypertrophic response in rats with myocardial infarction.
    Westendorp B; Schoemaker RG; Buikema H; de Zeeuw D; van Veldhuisen DJ; van Gilst WH
    J Renin Angiotensin Aldosterone Syst; 2004 Mar; 5(1):27-32. PubMed ID: 15136971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ACE activity during the hypotension produced by standardized aqueous extract of Cecropia glaziovii Sneth: a comparative study to captopril effects in rats.
    Ninahuaman MF; Souccar C; Lapa AJ; Lima-Landman MT
    Phytomedicine; 2007 May; 14(5):321-7. PubMed ID: 17433647
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic resistance to angiotensin converting enzyme (ACE) inhibition is related to pharmacodynamic and -kinetic factors in 5/6 nephrectomized rats.
    Windt WA; van Dokkum RP; Kluppel CA; Jeronimus-Stratingh CM; Hut F; de Zeeuw D; Henning RH
    Eur J Pharmacol; 2008 Feb; 580(1-2):231-40. PubMed ID: 18036585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of renal ACE activity in proteinuria-associated renal damage in untreated and treated adriamycin nephrotic rats.
    Bos H; Laverman GD; Henning RH; Tiebosch AT; de Jong PE; de Zeeuw D; Navis G
    J Renin Angiotensin Aldosterone Syst; 2003 Jun; 4(2):106-12. PubMed ID: 12806593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individual differences in renal ACE activity in healthy rats predict susceptibility to adriamycin-induced renal damage.
    Rook M; Lely AT; Kramer AB; van Goor H; Navis G
    Nephrol Dial Transplant; 2005 Jan; 20(1):59-64. PubMed ID: 15572383
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Slowing the progression of chronic renal insufficiency with captopril in rats with spontaneous arterial hypertension and adriamycin nephropathy].
    Jovanović DB; Jovović Dj; Varagić J; Dimitrijević J; Dragojlović Z; Djukanović L
    Srp Arh Celok Lek; 2002; 130(3-4):73-80. PubMed ID: 12154518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: role of sodium status.
    van der Kleij FG; Schmidt A; Navis GJ; Haas M; Yilmaz N; de Jong PE; Mayer G; de Zeeuw D
    Kidney Int Suppl; 1997 Dec; 63():S23-6. PubMed ID: 9407415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of carvedilol on pulse pressure and left ventricular hypertrophy in spontaneously hypertensive rats with adriamycin nephropathy.
    Jovanovic D; Jovovic D; Mihailovic-Stanojevic N; Miloradovic Z; Naumovic R; Dimitrijevic J; Maksic N; Djukanovic L
    Biomed Pharmacother; 2009 Sep; 63(8):571-6. PubMed ID: 19013753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective effects of ACE inhibitors on vascular endothelial dysfunction induced by exogenous advanced oxidation protein products in rats.
    Chen SX; Song T; Zhou SH; Liu YH; Wu SJ; Liu LY
    Eur J Pharmacol; 2008 Apr; 584(2-3):368-75. PubMed ID: 18334254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
    Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
    Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the effects of converting-enzyme inhibition and protein restriction in experimental nephrosis.
    Beukers JJ; Hoedemaeker PJ; Weening JJ
    Lab Invest; 1988 Nov; 59(5):631-40. PubMed ID: 3054313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?
    Raasch W; Bartels T; Schwartz C; Häuser W; Rütten H; Dominiak P
    J Hypertens; 2002 Dec; 20(12):2495-504. PubMed ID: 12473875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does angiotensin (1-7) contribute to the anti-proteinuric effect of ACE-inhibitors.
    van der Wouden EA; Henning RH; Deelman LE; Roks AJ; Boomsma F; de Zeeuw D
    J Renin Angiotensin Aldosterone Syst; 2005 Sep; 6(2):96-101. PubMed ID: 16470489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.